KPTI - Karyopharm Therapeutics GAAP EPS of -$0.29 beats by $0.06 revenue of $37.6M beats by $1.93M

2023-08-02 07:43:12 ET

• Karyopharm Therapeutics press release ( NASDAQ: KPTI ): Q2 GAAP EPS of -$0.29 beats by $0.06 .
• Revenue of $37.6M (-5.2% Y/Y) beats by $1.93M .

• Net product revenue: Net product revenue for the second quarter of 2023 was $28.5 million, compared with $29.0 million for the second quarter of 2022.

  License and other revenue: License and other revenue for the second quarter of 2023 was $9.1 million, compared to $10.7 million for the second quarter of 2022.

• Cash position: Cash, cash equivalents, restricted cash and investments as of June 30, 2023, totaled $237.7 million, compared to $279.7 million as of December 31, 2022.

• FY Outlook: Total revenue to be in the range of $145 million to $160 million. U.S. XPOVIO net product revenue to be in the range of $110 million to $125 million, driven by the expectation that the increased use of PAP will continue in 2023, including a cumulative effect from refills. Non-GAAP R&D and SG&A expenses*, which exclude stock-based compensation expense, to be in the range of $240 million to $255 million.

For further details see: